Researchers at Baylor College of Medicine have discovered a natural mechanism that clears existing amyloid plaques in the brains of mouse models of Alzheimer's disease and preserves cognitive function ...

A protein notorious for its role in Alzheimer’s disease may hold the key to supercharging the aging immune system, according to new research. Scientists have found that a byproduct of amyloid-beta ...

Every participant in the Dutch 100-Plus study is, by definition, exceptional. Just to qualify for enrollment, they must have remained cognitively healthy even after logging 100 laps around the sun.

Amyloid heart disease occurs when amyloid fibrils build up in the heart, making it more difficult for the heart to pump blood around the body. Eventually, this can lead to heart failure. People can ...

More than half of 95 centenarians had a low amyloid load and 9% had no amyloid, autopsy data showed. A third of centenarians had a high amyloid load comparable to Alzheimer's disease. Five ...

The FDA expanded the uses of GE HealthCare’s Vizamyl imaging agent for highlighting the presence of beta amyloid proteins in the brain, with new green lights that enable more objective scans and the ...

The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is the first blood test aiding Alzheimer's diagnosis by detecting amyloid plaques, offering a less invasive alternative to PET scans. The test ...

Findings showed 91.7% of patients with positive results using Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test had amyloid plaques based on PET scan or CSF test results. The Food and Drug ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance to the first blood test to aid in diagnosing Alzheimer’s disease (AD). The Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio, ...

Scientists unveil a novel supramolecular therapy that shields human neurons from amyloid-induced damage, offering new hope for treating Alzheimer’s and related neurodegenerative diseases. Study: ...

Medications like lecanemab (Leqembi) and donanemab (Kisunla) target amyloid plaques in the brain that build up due to Alzheimer’s disease. They may help slow disease progression for people in the ...